NCT01332331 - Efficacy and Safety of Ambrisentan in Children 8-18yrs | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2011

Primary Completion Date

November 12, 2013

Study Completion Date

November 12, 2013

Conditions

Hypertension, Pulmonary

Interventions

DRUG

Ambrisentan - low dose

body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg

DRUG

Ambrisentan - high dose

body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg

Trial Locations (24)

1096

GSK Investigational Site, Budapest

1118

GSK Investigational Site, Ciudad de Buenos Aires

5000

GSK Investigational Site, Córdoba

5521

GSK Investigational Site, Guymallen

10032

GSK Investigational Site, New York

13353

GSK Investigational Site, Berlin

20097

GSK Investigational Site, San Donato Milanese (MI)

28046

GSK Investigational Site, Madrid

31059

GSK Investigational Site, Toulouse

33604

GSK Investigational Site, Pessac

35385

GSK Investigational Site, Giessen

75743

GSK Investigational Site, Paris

80045

GSK Investigational Site, Aurora

91054

GSK Investigational Site, Erlangen

125412

GSK Investigational Site, Moscow

630055

GSK Investigational Site, Novosibirsk

650002

GSK Investigational Site, Kemerovo

02115

GSK Investigational Site, Boston

48109-4204

GSK Investigational Site, Ann Arbor

00165

GSK Investigational Site, Rome

232-8555

GSK Investigational Site, Kanagawa

565-0871

GSK Investigational Site, Osaka

104-8560

GSK Investigational Site, Tokyo

143-8541

GSK Investigational Site, Tokyo